期刊文献+

维A酸受体β在食管鳞癌组织中的表达及其与化疗疗效的关系 被引量:2

The relationship between retinoic acid receptor-β expression and chemotherapy response in esophageal squamous cell carcinoma
原文传递
导出
摘要 目的 观察维A酸受体β(RAR-β)在食管鳞癌中的表达及其与化疗疗效的关系.方法 52例中晚期食管鳞癌患者给予以顺铂(DDP)+5-氟尿嘧啶(5-FU)为基础的联合方案化疗.DDP 80 mg/m2,分为5 d静脉滴注;5-FU每日375 mg/m2,第1~5天静脉滴注,21 d为1个周期.应用免疫组化法检测RAR-β在食管鳞癌组织中的表达.以50例正常食管黏膜作为对照.结果 RAR-β阳性染色主要位于细胞质和(或)胞核,食管鳞癌组织中RAR-β阳性率(61.5%,32/52)明显低于正常食管黏膜组织(92.0%,46/50),P<0.05.52例食管鳞癌患者共完成228个化疗周期,总有效率71.2%,RAR-β阳性表达者有效率84.4%(27/32),显著高于RAR-β阴性表达者的50.0%(10/20),P<0.05.RAR-β阳性表达者中位疾病进展时间为5.9个月,中位生存时间12.1个月,2年生存率56.7%;而RAR-β阴性表达者中位疾病进展时间为2.1个月,中位生存时间5.8个月,2年生存率32.9%,两组间比较差异均有统计学意义(P<0.05).结论 免疫组化法检测RAR-β的表达可作为临床上预测食管癌化疗疗效及预后的指标之一,同时RAR-β可能成为食管癌治疗的靶点. Objective To observe the relationship between expression of retinoic acid receptor-β (RAR-β) in esophageal squamous cell carcinoma (ESCC) and chemotherapy response. Methods Fifty-two cases advanced ESCC patients treated by DDP and 5-FU, DDP 80 mg/m2, divided into 5 days;5-FU 375 mg/m2, dl-5. Immunohistochemistry was used to exmine the expression of RAR-β in ESCC. Fifty cases normal esophageal tissue were used as controls. Results RAR-β immunoreactivity was recognizd in both cytoplasm and nucleus, RAR-β positive rate was lower in ESCC compared with normal tissue (61.5%vs 92% ,P <0. 05 ). The 52 cases ESCC patients were treated 228 chemotherapy cycles, the overall response rate (OR) was 71.2%. The OR in RAR-β positive patients was 84. 4% (27/32), significant higher than RAR-β negative patients 50. 0% ( 10/20 ) ( P < 0. 05 ). The time-to-progression ( TTP ) for RAR-β positive patients was 5.9 months, the median survival period was 12. 1 months, 2 years survival rate was 56. 7%;whereas TTP for RAR-β negative patients was 2. 1 months, the median survival period was 5.8 months,2 years survival rate was 32. 9%. There was signifcant difference between the 2 groups ( P < 0. 05 ) .Conclusion RAR-β protein expression by immunohistochemistry may be a useful indicator to predict the chemotherapy response and clinical outcome for ESCC, meanwhile it may be an avenue for target therapy.
出处 《中华内科杂志》 CAS CSCD 北大核心 2010年第10期848-850,共3页 Chinese Journal of Internal Medicine
基金 河南省自然科学基金资助项目(611040600)
关键词 食管肿瘤 受体 维甲酸 药物疗法 Esophageal neoplasms Receptor,retinoic acid Drug therapy
  • 相关文献

参考文献6

二级参考文献85

共引文献67

同被引文献10

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部